Jim Cramer Highlights ‘Transformational’ Impact Of Weight Loss Drugs Like Ozempic: Focus Now On ‘Potential Winners’ From The Same Narrative – Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)

Jim Cramer, the well-known television personality and investment expert, recently discussed the investment potential of GLP-1 drugs. These drugs, commonly used for diabetes and obesity treatment, are experiencing growing demand and could have a significant impact on the market.

Initially, investors had concerns about the market impact of these drugs. However, with the market’s recent recovery, Cramer suggests focusing on stocks that stand to benefit from the increased demand for GLP-1 drugs.

Some immediate beneficiaries of this trend include leading GLP-1 companies Eli Lilly And Co (LLY) and Novo Nordisk A/S (NVO), the manufacturer of Ozempic. Cramer also mentioned the potential for these drugs to treat conditions beyond obesity and diabetes, such as heart disease, kidney disease, and alcoholism.

In addition to pharmaceutical companies, there are other sectors that could benefit from the growing demand for GLP-1 drugs. High-protein food manufacturers like Tyson Foods and Hormel Foods could see increased sales as people seek healthier options. Construction companies specializing in creating pharmaceutical manufacturing facilities, like Jacobs Solutions, may also experience growth. Even the apparel sector, with brands like Levi’s already benefiting from changes in customer sizes, holds potential according to Cramer.

Cramer notes that when the market was struggling, concerns were raised about the potential loss of revenue for food companies due to the popularity of these weight loss drugs. But now that the market is more optimistic, the focus has shifted to potential winners in this story.

The recent focus on obesity treatment in the pharmaceutical industry indicates a shift in market dynamics. Companies with obesity drugs in their portfolio, such as Novo Nordisk and Eli Lilly, have seen significant increases in their share prices.

Competition in this space is also heating up, with Roche Holding AG recently acquiring Carmot Therapeutics, a privately held obesity company. Roche aims to rival Novo Nordisk and Eli Lilly in the weight-loss drug market. This acquisition highlights the growing importance and potential profitability of GLP-1 drugs.

These developments create new opportunities for investors in various sectors, from pharmaceuticals to food and construction. The potential for GLP-1 drugs to treat a range of conditions beyond obesity and diabetes opens up even more possibilities for growth.

As always, it’s important for investors to conduct thorough research and consider their own investment strategies before making any decisions. However, Cramer’s insights provide valuable perspective on the growing demand for GLP-1 drugs and the potential investment opportunities that come with it.